BUSINESS MATTERS MAG: How Sir Evelyn de Rothschild’s Foundation Helped Fund the Search for Alzheimer’s Treatments

When results from a British clinical trial of a repurposed diabetes drug reached a leading medical journal in December 2025, the finding carried a quiet backstory about who pays for early science.

The study suggested that liraglutide could slow cognitive decline and brain shrinkage in people with mild Alzheimer’s disease. Years before those headlines appeared, the philanthropic record of Sir Evelyn de Rothschild had already touched this field through the family foundation he built around medical research. His giving offers a useful case study in how private capital underwrites experimental work long before any result is certain, and in how a single grant can travel a long way from the donor who signs it.

Read the Full Article